Anixa Biosciences
ANIX
14 hedge funds and large institutions have $169K invested in Anixa Biosciences in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
27% more funds holding
Funds holding: 11 → 14 (+3)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.5% less ownership
Funds ownership: 1.48% → 0.98% (-0.5%)
56% less capital invested
Capital invested by funds: $385K → $169K (-$216K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$17.4K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$5.7K |
| 3 |
IA
IFP Advisors
Tampa,
Florida
|
+$1.39K |
| 4 |
JP Morgan Chase
New York
|
+$1.24K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$111 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1 |
ANIX Hedge Fund Activity: Q2 2017 in Review
14 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q2 2017, worth a combined $169K — down 56% from $385K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ANIX positions and 1 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $17.4K. The largest seller was Vanguard Group, cutting an estimated $1.
- 14 institutional investors held Anixa Biosciences (ANIX) as of Q2 2017, up from 11 in Q1 2017.
- Funds reported $169K of Anixa Biosciences stock for Q2 2017, down 56% quarter-over-quarter.
- 4 funds opened new Anixa Biosciences positions in Q2 2017 and 1 closed out, a net change of +3 holders.
- The largest Anixa Biosciences buyer in Q2 2017 was Virtu KCG Holdings, an estimated $17.4K added.
- The largest Anixa Biosciences seller in Q2 2017 was Vanguard Group, an estimated $1 sold.
Based on aggregated 13F filings for Q2 2017.